The addition of pembrolizumab to chemotherapy as a first line treatment appears to provide a progression-free survival benefit to patients diagnosed with triple-negative breast cancer when compared to chemotherapy alone, researchers reported at the ASCO 2020 virtual congress. Patients whose tumours contained higher levels of PD-L1 – the target of pembrolizumab — achieved four months ...
Early treatment with pembrolizumab may help in triple negative breast cancer
By Ed Susman
5 Jun 2020